PsyBio-11142

**PsyBio-11142** is a proprietary biosynthetic tryptamine developed by PsyBio Therapeutics Corp. using genetically engineered bacteria for scalable production. It belongs to a novel class of psycho-targeted therapeutics derived from naturally occurring psychoactive compounds found in hallucinogenic mushrooms, designed to treat mental health disorders by modulating brain synaptic and neurotransmitter activity to stimulate the reward system and promote neural rewiring through altered perception and contemplation. As PsyBio's lead candidate, it has received government approval for manufacturing at scale, positioning it as a potential next-generation psychedelic therapy ahead of planned human clinical trials.[1][2][4][5]